{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "VREX",
  "name": "Varex Imaging Corporation",
  "url": "https://frontierpicks.com/dossiers/VREX/",
  "json_url": "https://frontierpicks.com/dossiers/VREX.json",
  "status": "WATCHLIST",
  "current_conviction": "HIGH",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.",
  "invalidation_trigger": "A daily close below $17.50 invalidates the completion-price thesis, retaining the research threshold published on 2026-09-03; it does not by itself establish that the merger has terminated.",
  "catalyst_date": "2026-10-02",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "All-cash deal signed 2026-08-10 at $18.90/share: upside is contractually capped absent a superior proposal.",
    "Merger agreement terms: $25.3M termination fee, 2027-05-10 outside date, no financing condition.",
    "Stockholder adoption requires a majority of shares outstanding, not merely a majority of votes cast.",
    "Closing conditions span HSR, foreign merger-control laws and foreign investment (FDI) laws, per the 2026-08-10 8-K.",
    "Varex cancelled its fiscal Q3 2026 earnings call because of the pending transaction; fiscal year ends early October.",
    "On completion the shares are delisted from Nasdaq and cease to exist as a traded instrument."
  ],
  "body_markdown": "## Current Thesis\n\nVarex Imaging Corporation’s thesis remains completion of Teledyne’s signed $18.90-per-share cash acquisition; payment settles the case, while a daily close below $17.50 invalidates the published price thesis. The companies announced the agreement on 2026-08-10 and guided completion to early calendar 2027. [Joint announcement](https://www.teledyne.com/en-us/news/Pages/teledyne-to-acquire-varex-imaging-corporation.aspx)\n\nThe material change since the 2026-09-03 dossier is procedural: Varex filed its preliminary merger proxy on 2026-09-08. The previous concern about an absent proxy has therefore been resolved. The company’s filing list, checked on 2026-09-13, shows that document as its latest filing. [Varex filing record](https://www.vareximaging.com/sec-filings/)\n\nThe narrative is saturated — an inference anchored in Sidoti’s 2026-08-10 downgrade to Neutral, Oppenheimer’s 2026-08-11 downgrade to Perform, and Benzinga’s 2026-08-14 weekly deal roundup. Those dated observations establish that the acquisition story is already broadly circulated; they do not measure investor crowding.\n\n## Bull Case\n\n- **Cash terms remove financing conditionality.** The 2026-08-10 agreement specifies $18.90 per share and contains no financing condition. This supports the completion case, although regulatory and stockholder conditions remain. [Merger announcement filing](https://www.sec.gov/Archives/edgar/data/1681622/000110465926093349/tm2622593d1_8k.htm)\n- **The filing process has advanced.** The 2026-09-08 preliminary proxy supersedes the missing-document concern in the 2026-09-03 dossier. It establishes progress toward solicitation, without establishing approval. [SEC filing receipt](https://www.sec.gov/Archives/edgar/data/1681622/000110465926105957/0001104659-26-105957-index.htm)\n\n## Bear Case\n\n- **Regulatory scope is now explicit.** The 2026-09-08 proxy identifies antitrust reviews in Austria, China, Germany, Japan, Saudi Arabia and Ukraine, plus United Kingdom investment screening. These are required approvals, not evidence of objections. [Preliminary proxy](https://www.sec.gov/Archives/edgar/data/1681622/000110465926105957/tm2622593-4_prem14a.htm)\n- **Operating cash generation remains weak.** Varex’s quarter-ended 2026-07-03 financial statements reported nine-month operating cash flow of $3.4 million versus $33.8 million a year earlier, with inventories of $347.1 million versus $299.4 million. This limits the evidence for a strong standalone fallback if the agreement terminates; it does not establish a termination right.\n\n## Setup & Price Structure\n\nThe adjusted market close was $18.46 on 2026-09-11, against a supplied 52-week high of $18.58 and a three-month price increase of 67.2%. The contractual cash consideration remains $18.90 under the 2026-08-10 agreement. These observations describe a price below the acquisition consideration; they do not identify the market’s implied completion probability.\n\nNo moving-average series, volume history or current ownership-flow measurements accompany the 2026-09-11 snapshot. The sample is too small to support a claim about expanding participation, retail crowding or a new technical base. The $17.50 threshold remains the research invalidation published on 2026-09-03, rather than a newly verified support shelf.\n\n## Catalyst Calendar (next 30 days)\n\nThe 2026-09-08 proxy leaves the special-meeting date and Hart-Scott-Rodino antitrust filing and expiry dates blank. No dated merger catalyst is established inside the next 30 days. [Preliminary proxy](https://www.sec.gov/Archives/edgar/data/1681622/000110465926105957/tm2622593-4_prem14a.htm)\n\n- **2026-10-02 — Fiscal year end.** The SEC’s 2026-09-08 filing metadata identifies this fiscal year-end calendar point. It is neither an earnings-release date nor a merger approval. [SEC filing metadata](https://www.sec.gov/Archives/edgar/data/1681622/000110465926105957/0001104659-26-105957-index.htm)\n- **2027-05-10 — Initial outside date.** The 2026-09-08 proxy permits extension to 2027-08-10 under specified unresolved-regulatory conditions. The initial date is therefore not an unconditional termination deadline. [Preliminary proxy](https://www.sec.gov/Archives/edgar/data/1681622/000110465926105957/tm2622593-4_prem14a.htm)\n\n## What Would Change Our Mind\n\nLoss of the published completion-price structure would invalidate the case: a daily close below $17.50 is the observable breach, retaining the threshold disclosed on 2026-09-03. That condition records failure of the price thesis without claiming that the transaction itself must then fail.\n\nThe former 2026-09-28 missing-proxy checkpoint is retired because the document arrived on 2026-09-08. Undisclosed antitrust dates establish uncertainty, not evidence of an adverse regulatory decision. [Preliminary proxy](https://www.sec.gov/Archives/edgar/data/1681622/000110465926105957/tm2622593-4_prem14a.htm)\n\n## Correlation Notes\n\nThis is a single-company completion thesis. The 2026-08-10 agreement fixes cash consideration rather than an exchange ratio tied to Teledyne’s share price. [Merger announcement filing](https://www.sec.gov/Archives/edgar/data/1681622/000110465926093349/tm2622593d1_8k.htm) No paired return series accompanies the 2026-09-11 price snapshot, so a measured correlation with medical technology equities, Teledyne or merger-arbitrage funds cannot be stated.",
  "first_seen": "2026-08-11",
  "last_analyzed": "2026-09-13T11:39:14+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}